--- title: "AnaptysBio (ANAB) news: lawsuit" url: "https://aibio.space/companies/anaptysbio/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ANAB lawsuit news: AnaptysBio awaits post-trial argument in Delaware suit against GSK and Tesaro. AnaptysBio, Inc. (NASDAQ: ANAB), United States." --- ANAB AnaptysBio, Inc. NASDAQ · United States # AnaptysBio (ANAB) news ANAB lawsuit news Legal · 2026-09-21 ## [AnaptysBio awaits post-trial argument in Delaware suit against GSK and Tesaro](https://aibio.space/news/anaptysbio-awaits-post-trial-argument-delaware-suit-against-gsk-tesaro/) AnaptysBio sued TESARO, Inc. and GSK on Nov. 20, 2025 over the dostarlimab collaboration. Trial ended July 17, 2026, and post-trial argument is set for Oct. 20. Tesaro's claim that AnaptysBio breached its duties was dismissed April 24. ## Latest AnaptysBio news 1. 2026-04-20 Mergers [AnaptysBio completes spin-off of First Tracks Biotherapeutics, keeps royalty business](https://aibio.space/news/anaptysbio-completes-spin-off-first-tracks-biotherapeutics/) AnaptysBio completed the spin-off of First Tracks Biotherapeutics on April 20, 2026, one share for every share held on April 6. AnaptysBio keeps the royalty business and gives a range of $140-$145 million for its net cash, while the press release calls the spin-off taxable and cites an EBIT margin it does not reconcile to GAAP. 2. 2026-04-20 Mergers [AnaptysBio completes spin-off of First Tracks Biotherapeutics](https://aibio.space/news/anaptysbio-completes-spin-off-first-tracks-biotherapeutics/) Shareholders received one First Tracks share for each AnaptysBio share held on April 6, 2026. AnaptysBio now manages two royalty collaborations and starts with about $140-$145 million in net cash. 3. 2026-03-27 Financings [AnaptysBio board approves First Tracks spin-off, set to launch with $180 million](https://aibio.space/news/anaptysbio-board-approves-first-tracks-spin-off-set-launch-180-million/) AnaptysBio will spin off First Tracks Bio on April 20, 2026 with $180 million of cash, $100 million of it from AnaptysBio itself, and the release gives no results for the spun-off company's lead programs. 4. 2025-11-21 Legal [AnaptysBio sues Tesaro and GSK in Delaware Chancery Court over Jemperli collaboration](https://aibio.space/news/anaptysbio-sues-tesaro-gsk-delaware-chancery-court-jemperli/) AnaptysBio's Verified Complaint of Nov 20, 2025 names Tesaro, Inc. and its parent GlaxoSmithKline and alleges breaches of the Jemperli collaboration. Tesaro sued AnaptysBio the same day, and the parties have agreed to ask for an expedited schedule. 5. 2024-11-05 Financings [AnaptysBio files $500,000,000 shelf with a $100,000,000 stock sales program](https://aibio.space/news/anaptysbio-files-500-000-000-shelf-100-000-000-stock-sales-program/) AnaptysBio's new shelf replaces one that expires January 11, 2025, and its $100,000,000 sales program with TD Securities (USA) LLC could sell up to 4,819,277 shares at $20.75 each, with immediate dilution of $15.59 per share for new buyers. ## AnaptysBio at a glance - **Ticker**: ANAB - **Listing**: NASDAQ - **Country**: United States - **Cash, Mar 31, 2026**: $286.5 million ### Related companies - [Natera](https://aibio.space/companies/natera/) NASDAQ: NTRA - [Ensysce Biosciences](https://aibio.space/companies/ensysce-biosciences/) NASDAQ: ENSC - [Boundless Bio](https://aibio.space/companies/boundless-bio/) NASDAQ: BOLD - [BioCardia](https://aibio.space/companies/biocardia/) NASDAQ: BCDA - [ProKidney](https://aibio.space/companies/prokidney/) NASDAQ: PROK - [GB Sciences](https://aibio.space/companies/gb-sciences/) OTC: GBLX - [Anixa Biosciences](https://aibio.space/companies/anixa-biosciences/) NASDAQ: ANIX - [4D Molecular Therapeutics](https://aibio.space/companies/4d-molecular-therapeutics/) NASDAQ: FDMT ### Also on NASDAQ - [Savara](https://aibio.space/companies/savara/) SVRA - [Apnimed](https://aibio.space/companies/apnimed/) APMD - [Eikon Therapeutics](https://aibio.space/companies/eikon-therapeutics/) EIKN - [Cronos Group](https://aibio.space/companies/cronos/) CRON - [Cytek Biosciences](https://aibio.space/companies/cytek-biosciences/) CTKB - [Evaxion](https://aibio.space/companies/evaxion/) EVAX ## AnaptysBio annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$234.6 million](https://www.sec.gov/Archives/edgar/data/1370053/000119312526088290/) | [$91.3 million](https://www.sec.gov/Archives/edgar/data/1370053/000119312526088290/) | | Net income (loss) | [-$13.2 million](https://www.sec.gov/Archives/edgar/data/1370053/000119312526187044/) | [-$145.2 million](https://www.sec.gov/Archives/edgar/data/1370053/000119312526187044/) | | Cash from operations | [$19.7 million](https://www.sec.gov/Archives/edgar/data/1370053/000119312526088290/) | [-$135.3 million](https://www.sec.gov/Archives/edgar/data/1370053/000119312526088290/) | | Cash and equivalents | [$238.2 million](https://www.sec.gov/Archives/edgar/data/1370053/000119312526219515/) | [$123.1 million](https://www.sec.gov/Archives/edgar/data/1370053/000119312526088290/) | | Short-term investments | [$73.4 million](https://www.sec.gov/Archives/edgar/data/1370053/000119312526219515/) | [$262.3 million](https://www.sec.gov/Archives/edgar/data/1370053/000119312526088290/) | Latest balance sheet, Mar 31, 2026 (10-Q): cash and equivalents $248.5 million, plus short-term investments of $38.0 million, $286.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about AnaptysBio Is AnaptysBio involved in a lawsuit? Our latest story on this, dated Sep 21, 2026: "AnaptysBio awaits post-trial argument in Delaware suit against GSK and Tesaro". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/anaptysbio-awaits-post-trial-argument-delaware-suit-against-gsk-tesaro/). What is the ticker symbol of AnaptysBio? AnaptysBio, Inc. trades under the ticker ANAB on NASDAQ. Where is AnaptysBio listed? AnaptysBio, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:AN6; LSE:0HFQ. What is the SEC CIK of AnaptysBio? The SEC Central Index Key (CIK) for AnaptysBio, Inc. is 1370053. Its filings are on SEC EDGAR. How many shares does AnaptysBio have outstanding? 29,100,902 shares as of 2026-05-07, per the cover page of its 10-Q filed 2026-05-12. Which country or territory is AnaptysBio listed under? Our directory records AnaptysBio, Inc. under United States. What does AnaptysBio do? Our directory classifies AnaptysBio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of AnaptysBio? The ISIN recorded for AnaptysBio, Inc. is US0327241065. Does aibio.space cover AnaptysBio? aibio.space lists AnaptysBio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is AnaptysBio incorporated? SEC records list its state or country of incorporation as DE. What was AnaptysBio's revenue last year? $234.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is AnaptysBio profitable? AnaptysBio, Inc. reported a net loss of $13.2 million for the fiscal year ended Dec 31, 2025, and generated $19.7 million of cash from operations, per its annual report to the SEC. How much cash does AnaptysBio have? $286.5 million in cash and short-term investments at Mar 31, 2026, per its 10-Q. What is the latest AnaptysBio (ANAB) stock news? Our latest story on AnaptysBio, dated Sep 21, 2026: "AnaptysBio awaits post-trial argument in Delaware suit against GSK and Tesaro". AnaptysBio sued TESARO, Inc. and GSK on Nov. 20, 2025 over the dostarlimab collaboration. Trial ended July 17, 2026, and post-trial argument is set for Oct. 20. Tesaro's claim that AnaptysBio breached its duties was dismissed April 24. [Source](https://aibio.space/news/anaptysbio-awaits-post-trial-argument-delaware-suit-against-gsk-tesaro/). What is AnaptysBio's latest stock offering or financing news? Our latest financing story, dated Mar 27, 2026: "AnaptysBio board approves First Tracks spin-off, set to launch with $180 million". AnaptysBio will spin off First Tracks Bio on April 20, 2026 with $180 million of cash, $100 million of it from AnaptysBio itself, and the release gives no results for the spun-off company's lead programs. [Source](https://aibio.space/news/anaptysbio-board-approves-first-tracks-spin-off-set-launch-180-million/). ## Investor discussion: AnaptysBio Members talk about AnaptysBio (ANAB). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at AnaptysBio, newest first. Each line links the filing it comes from. 1. 2026-04-20 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1370053/000119312526164330/d120122dex991.htm) 2. 2026-03-27 Financings Reported a financing. SEC Form 8-K (Items 1.01,1.02,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1370053/000119312526127783/d122216dex991.htm) 3. 2024-11-05 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1370053/000137005324000056/anab-formsx3_atm2024.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ANAB on TradingView](https://www.tradingview.com/symbols/NASDAQ-ANAB/). ## SEC filings and registration - **SEC name**: Anaptysbio, Inc - **CIK**: 1370053 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ANAB (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: June 30 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121 - **Phone**: 858-362-6295 - **Shares outstanding**: 29,100,902 as of 2026-05-07 (10-Q filed 2026-05-12) - **Former names**: ANAPTYSBIO INC; ANAPTYS BIOSCIENCES INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1370053/000119312526396690/anab-20260921.htm) filed 2026-09-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1370053/000119312526344583/anab-20260811.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1370053/000119312526326097/anab-20260728.htm) filed 2026-07-30 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1370053/000119312526288408/anab-20260629.htm) filed 2026-06-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1370053/000119312526277505/anab-20260615.htm) filed 2026-06-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1370053/000119312526248326/anab-20260529.htm) filed 2026-05-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1370053/000119312526234419/anab-20260518.htm) filed 2026-05-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1370053/000119312526219515/anab-20260331.htm) filed 2026-05-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001370053), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details AnaptysBio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ANAB, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: AnaptysBio, Inc. - **Ticker**: ANAB - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US0327241065 - **Other listed symbols**: GETTEX:AN6; LSE:0HFQ - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ANAB/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/anaptysbio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "AnaptysBio (ANAB) news: lawsuit", 2026-10-31, https://aibio.space/companies/anaptysbio/